Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
OBJECTIVE To document the acceptability of treatment with long-acting injectable (LAI) antipsychotic medication to early-phase schizophrenia patients as demonstrated by enrollment in a cluster-randomized LAI clinical trial. METHODS Eligible patients aged 18-35 years with a DSM-5 diagnosis of schizophrenia and less than 5 years of lifetime antipsychotic use were recruited between December 2014 and December 2016. Training for LAI antipsychotic site staff included education regarding the role of nonadherence in relapse/hospitalization and the rationale for LAI antipsychotic use with early-psychosis patients, training in shared decision-making and communication strategies, review of frequently asked questions about LAI antipsychotics, and role-playing to develop skills and solutions to overcoming LAI antipsychotic logistical barriers. Study prescribers also received training on prescribing guidelines. RESULTS At the 19 US outpatient clinics randomized to provide LAI antipsychotic treatment, 576 potential participants were identified who met inclusion criteria based on a screening interview. Of these, 83 (14.4%) declined participation because they would not consider LAI antipsychotic treatment and 165 (28.6%) declined for other reasons, resulting in 328 providing written study consent. The first post-consent visit included detailed evaluations to confirm inclusion/exclusion criteria. Thirty-nine participants who consented did not complete this evaluation and 55 were found to not m…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Still being checked.
Cited by
Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Achtyes, E. D., Gibbons, R. D., & Robinson, D. G. (2020) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2020.2076 · Cited by 208
Self-citationFiorillo, A., Barlati, S., Bellomo, A., Corrivetti, G., Nicolò, G., Sampogna, G., Stanga, V., Veltro, F., Maina, G., & Vita, A. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00293-4 · Cited by 110
“The SDM seems to be particularly effective in the case of LAIs prescription, since patient have prejudices and fears related to the formulation, which the doctor must contrast [35].”
BackgroundMethodInfluentialKane, J. M., McEvoy, J. P., Correll, C. U., & Llorca, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00861-6 · Cited by 93
Self-citationLong-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
Haddad, P. M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181073 · Cited by 63
Self-citationAdvances in Long-Acting Agents for the Treatment of HIV Infection
Rana, A., Castillo‐Mancilla, J., Tashima, K. T., & Landovitz, R. J. (2020) · Drugs · doi:10.1007/s40265-020-01284-1 · Cited by 52
Metadata
- Authors
- Kane, J. M., Schooler, N. R., Marcy, P., Achtyes, E. D., Correll, C. U., & Robinson, D. G.
- Affiliations
- Feinstein Institute for Medical Research (US)
- SUNY Downstate Health Sciences University (US)
- Vanguard (United States) (US)
- Grand Rapids Public Library (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2019-04-23
- Volume
- 80
- Issue
- 3
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W2940449852
- Semantic Scholar
- 586937481f09b596a545c8e029280b0933d876c8
- Cited by
- 58
- References
- 0
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 11 · 2023: 12 · 2022: 5 · 2021: 10 · 2020: 5 · 2019: 3
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Social Sciences › Psychology › Clinical Psychology › Healthcare Decision-Making and Restraints
- Keywords
- long-acting injectable antipsychotics, early-phase schizophrenia, treatment acceptability, treatment refusal, clinical trial recruitment, employee training, shared decision-making, outpatient clinics, young adults
- MeSH terms
- Aripiprazole, Decision Making, Shared, Adolescent, Adult, Delayed-Action Preparations, Female, Humans, Injections, Male, Patient Acceptance of Health Care, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, United States, Cohort Studies, Secondary Prevention, Young Adult, Early Medical Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. https://app.cochat.ai/papers/10.4088/jcp.18m12546
- The paper
- Kane, J. M., Schooler, N. R., Marcy, P., Achtyes, E. D., Correll, C. U., & Robinson, D. G. (2019). Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.18m12546
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.